肿瘤代谢成像:生物学基础与新兴策略
本文综述了肿瘤代谢失调的生物学基础,聚焦葡萄糖、谷氨酰胺和乙酸代谢;讨论了18F-FDG PET仅探测糖酵解早期步骤的局限性,以及新型PET放射性示踪剂和基于MR的方法等新成像技术如何拓展代谢成像手段,并强调联合多种模态进行多参数成像以全面表征肿瘤生物学、更好指导治疗的作用。
要点
- 18F-FDG PET仅探测糖酵解早期步骤,不能直接捕捉该通路早期步骤之后的代谢复杂性。
- 新型PET放射性示踪剂和基于MR的方法可探究细胞代谢的其他方面,拓展代谢成像手段。
- 联合多种模态进行多参数成像有助于全面表征肿瘤生物学,以更好地指导治疗。
核心结论
- 联合多种模态进行多参数成像将有助于全面表征肿瘤生物学,以更好地指导治疗。
研究设计与样本
- 综述,讨论肿瘤代谢失调的生物学基础,聚焦葡萄糖、谷氨酰胺和乙酸代谢,并在该生物学框架内讨论新型成像策略。
主要发现
- 18F-FDG PET利用异常的葡萄糖代谢进行成像,但仅探测糖酵解早期步骤,不能直接捕捉该单一路径早期步骤之后的代谢复杂性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dysregulated cellular metabolism is a characteristic feature of malignancy that has been exploited for both imaging and targeted therapy. With regard to imaging, deranged glucose metabolism has been leveraged using 18F-FDG PET. Metabolic imaging with 18F-FDG, however, probes only the early steps of glycolysis; the complexities of metabolism beyond these early steps in this single pathway are not directly captured. New imaging technologies-both PET with novel radiotracers and MR-based methods-provide unique opportunities to investigate other aspects of cellular metabolism and expand the metabolic imaging armamentarium. This review will discuss the underlying biology of metabolic dysregulation in cancer, focusing on glucose, glutamine, and acetate metabolism. Novel imaging strategies will be discussed within this biologic framework, highlighting particular strengths and limitations of each technique. Emphasis is placed on the role that combining modalities will play in enabling multiparametric imaging to fully characterize tumor biology to better inform treatment.
引用
- Pantel AR, Ackerman D, Lee SC, et al. Imaging Cancer Metabolism: Underlying Biology and Emerging Strategies. J Nucl Med. 2018. PMID: 30042161. doi:10.2967/jnumed.117.199869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。